A carregar...
Alemtuzumab in Covid era
BACKGROUND: The SARS-CoV-2 pandemic impact on people with Multiple Sclerosis (pwMS) continues to worry. The disease modifying therapies in pwMS can add a more severe risk of infection when compared to the general population. Alemtuzumab is an anti-CD52 monoclonal antibody and it is one of the most i...
Na minha lista:
| Publicado no: | Mult Scler Relat Disord |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier B.V.
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7969858/ https://ncbi.nlm.nih.gov/pubmed/33812222 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2021.102908 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|